Expanding Horizons in Pediatric Echocardiography with Ultrasound Enhancing Agents

The advent of ultrasound enhancing agents (UEAs) marked a milestone in the field of echocardiography. The FDA approved Optison (Perflutren Protein-Type A Microspheres) for use in adult echocardiography in 1997, which pioneered a new frontier in diagnostic clarity and efficiency for the patient, while providing the cardiac sonographer musculoskeletal relief when scanning technically challenging patients.

UEAs increase the echogenicity of the blood, provide cardiologists with a clearer, more detailed view of the heart, specifically enhancing the left ventricle’s endocardial boarder definition, revolutionizing adult echocardiography.

This leap in diagnostic capability is beneficial in cases where traditional echocardiography may fall short, particularly in patients with poor acoustic windows. The ability to visualize myocardial tissue with greater accuracy improves diagnostic accuracy which directly influences patient management and treatment.

Fast forward to December 2019, 22 years after the approval for use in adult echocardiography, the FDA approved Lumason (sulfur hexafluoride lipid-type A microspheres) for use in pediatric echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in pediatric patients with suboptimal echocardiograms.

However, the use of UEAs in pediatric echocardiography is a burgeoning field of exploration. Off-label use in pediatric echocardiography is vast, from enhancing endocardial border delineation to assess vessels and baffles in patients with congenital heart disease.

The integration of ultrasound enhancing agents (UEAs) into pediatric echocardiography represents a significant leap forward in our ability to diagnose and manage cardiac conditions in children. Despite the FDA approval, the journey of UEAs into mainstream pediatric echocardiography has been met with cautious optimism.

It is imperative to recognize and cultivate areas of growth that will ensure UEAs successful implementation and optimization. Four pillars of development stand out: healthcare provider education, patient education, industry support, and societal support. Each of these areas is crucial for the advancement of UEAs in pediatric cardiac care.

Healthcare Provider Education

The cornerstone of adopting any new medical advancement lies in comprehensive education for all healthcare providers involved. Physicians, nurse practitioners, and pediatric cardiac sonographers must be well-informed about the nuances of using UEAs, including the selection of appropriate cases, administration techniques, and interpretation of enhanced echocardiographic images. Tailored educational programs, workshops, and continuing medical education (CME) opportunities focusing on UEAs can bridge knowledge gaps and promote best practices.

Patient Education

Equally important is educating the patients and their families about the benefits and safety of UEAs. IV sticks in a pediatric patient can be a large feat to overcome. Ultrasound enhancing agent companies play a pivotal role in creating pediatric-friendly, engaging, and informative educational materials. These resources should demystify the procedure for children and caregivers alike, addressing common concerns and highlighting the importance of enhanced imaging in simple, reassuring language.

Cardiac Ultrasound Industry Support: The successful implementation of UEAs in pediatric echocardiography also hinges on support from the ultrasound equipment industry. Manufacturers must recognize the specific needs of pediatric echocardiography, such as the requirement for higher frequency transducers, and incorporate UEA presets that facilitate the optimal use of UEAs. This collaboration can drive innovation, streamline the imaging process, and ensure that the equipment meets the unique demands of pediatric cardiac imaging.

Societal Support

The support and leadership of the American Society of Echocardiography are crucial to advancing the use of ultrasound enhancing agents in pediatric echocardiography. Specifically, the establishment of a specialized arm on the ASE’s Contrast Zone page focusing on pediatric echocardiography could serve as a central hub for knowledge, advocacy, and research.

• Multi-Center Research Collaboration: One of the primary functions of this ASE arm could be to facilitate and promote multi-center research collaborations. Pediatric echocardiography utilizing UEAs, could benefit immensely from pooled resources and data. Multi-center studies can provide the robust evidence needed to refine the use of UEAs in children, offering insights into efficacy, safety, and novel applications.
• Task Force for Usage Guidelines: The creation of a task force dedicated to establishing guidelines for the use of UEAs in pediatric echocardiography is another critical area of focus. This task force would work on developing comprehensive guidelines that cover all aspects of UEA usage, from patient selection and consent to administration protocols and post-procedure monitoring. The guidelines would need to focus the pediatric population, ensuring that the use of UEAs is both safe and effective.
• Scope of Practice for Sonographers: Recognizing the differences in performing echocardiography in children compared to adults, another key initiative would be to delineate the scope of practice for pediatric cardiac sonographers. This includes defining the specific skills, knowledge, and competencies required to safely and effectively use UEAs in pediatric echocardiography. By establishing clear standards and expectations, the ASE can ensure that sonographers are well-equipped to navigate the complexities of UEAs with pediatric echocardiography.
• Adverse Reactions Task Force: Monitoring and documentation of adverse reactions are paramount to the safe use of UEAs. An adverse reactions task force, operating under the ASE’s guidance, could play a vital role in tracking, analyzing, and disseminating information about any adverse events associated with UEA use in children. This task force would not only contribute to the safety of current practices but also inform future guidelines and recommendations.

In conclusion, as we better understand the capabilities and applications of ultrasound enhancing agents in pediatric echocardiography, it's clear that we stand on the cusp of a new era in pediatric cardiac sonography. The integration of UEAs holds the promise of elevating the standard of diagnosis and management of cardiac conditions in children, combining the principles of safety, precision, and non-invasiveness.

However, it is imperative that this journey is lead by rigorous research, ethical considerations, and a steadfast commitment to optimizing pediatric cardiac health. The potential of UEAs in transforming pediatric echocardiography is immense, yet it calls for a collaborative, multidisciplinary effort to fully realize its benefits while safeguarding the well-being of our youngest patients.

Trust EDM's ultrasound probe covers for superior protection and fluid control.